LLY Quote, Financials, Valuation and Earnings

Moderna has a net margin of 8.48% compared to Eli Lilly and's net margin of 0.7%. Eli Lilly and's return on equity of 66.4% beat Moderna's return on equity of -17.44%.

Eli Lilly and has a consensus price target of $984.05, signalling upside risk potential of 25%. On the other hand Moderna has an analysts' consensus of $73.64 which suggests that it could grow by 70.59%. Given that Moderna has higher upside potential than Eli Lilly and, analysts believe Moderna is more attractive than Eli Lilly and.

Eli Lilly and has a beta of 0.413, which suggesting that the stock is 58.729% less volatile than S&P 500. In comparison Moderna has a beta of 1.597, suggesting its more volatile than the S&P 500 by 59.715%.

Eli Lilly and has a quarterly dividend of $1.30 per share corresponding to a yield of 0.66%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eli Lilly and pays 77.65% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Eli Lilly and quarterly revenues are $11.4B, which are larger than Moderna quarterly revenues of $1.9B. Eli Lilly and's net income of $970.3M is higher than Moderna's net income of $13M. Notably, Eli Lilly and's price-to-earnings ratio is 85.10x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eli Lilly and is 17.42x versus 3.30x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of 8.48% compared to Eli Lilly and's net margin of 36.03%. Eli Lilly and's return on equity of 66.4% beat Regeneron Pharmaceuticals's return on equity of 17.19%.

Eli Lilly and has a consensus price target of $984.05, signalling upside risk potential of 25%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $1,045.03 which suggests that it could grow by 42.46%. Given that Regeneron Pharmaceuticals has higher upside potential than Eli Lilly and, analysts believe Regeneron Pharmaceuticals is more attractive than Eli Lilly and.

Eli Lilly and has a beta of 0.413, which suggesting that the stock is 58.729% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.098, suggesting its less volatile than the S&P 500 by 90.217%.

Eli Lilly and has a quarterly dividend of $1.30 per share corresponding to a yield of 0.66%. Regeneron Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eli Lilly and pays 77.65% of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Eli Lilly and quarterly revenues are $11.4B, which are larger than Regeneron Pharmaceuticals quarterly revenues of $3.7B. Eli Lilly and's net income of $970.3M is lower than Regeneron Pharmaceuticals's net income of $1.3B. Notably, Eli Lilly and's price-to-earnings ratio is 85.10x while Regeneron Pharmaceuticals's PE ratio is 18.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eli Lilly and is 17.42x versus 6.10x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics has a net margin of 8.48% compared to Eli Lilly and's net margin of --. Eli Lilly and's return on equity of 66.4% beat Viking Therapeutics's return on equity of --.

Eli Lilly and has a consensus price target of $984.05, signalling upside risk potential of 25%. On the other hand Viking Therapeutics has an analysts' consensus of $110.00 which suggests that it could grow by 170.94%. Given that Viking Therapeutics has higher upside potential than Eli Lilly and, analysts believe Viking Therapeutics is more attractive than Eli Lilly and.

Eli Lilly and has a beta of 0.413, which suggesting that the stock is 58.729% less volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.947, suggesting its less volatile than the S&P 500 by 5.344%.

Eli Lilly and has a quarterly dividend of $1.30 per share corresponding to a yield of 0.66%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eli Lilly and pays 77.65% of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Eli Lilly and quarterly revenues are $11.4B, which are larger than Viking Therapeutics quarterly revenues of --. Eli Lilly and's net income of $970.3M is higher than Viking Therapeutics's net income of -$24.9M. Notably, Eli Lilly and's price-to-earnings ratio is 85.10x while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eli Lilly and is 17.42x versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of 8.48% compared to Eli Lilly and's net margin of 37.71%. Eli Lilly and's return on equity of 66.4% beat Vertex Pharmaceuticals's return on equity of -2.89%.

Eli Lilly and has a consensus price target of $984.05, signalling upside risk potential of 25%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $493.64 which suggests that it could grow by 19.78%. Given that Eli Lilly and has higher upside potential than Vertex Pharmaceuticals, analysts believe Eli Lilly and is more attractive than Vertex Pharmaceuticals.

Eli Lilly and has a beta of 0.413, which suggesting that the stock is 58.729% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.399, suggesting its less volatile than the S&P 500 by 60.102%.

Eli Lilly and has a quarterly dividend of $1.30 per share corresponding to a yield of 0.66%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eli Lilly and pays 77.65% of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Eli Lilly and quarterly revenues are $11.4B, which are larger than Vertex Pharmaceuticals quarterly revenues of $2.8B. Eli Lilly and's net income of $970.3M is lower than Vertex Pharmaceuticals's net income of $1B. Notably, Eli Lilly and's price-to-earnings ratio is 85.10x while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eli Lilly and is 17.42x versus 10.09x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.